New hope for tough leukemia in younger patients
NCT ID NCT04269213
Summary
This study is testing how well a chemotherapy drug called CPX-351 works for adults under 60 with secondary acute myeloid leukemia, a type of blood cancer that develops from other blood disorders or previous cancer treatments. The goal is to see if this drug can help patients achieve remission and potentially proceed to a stem cell transplant. Researchers will measure how many patients respond to treatment, how long the response lasts, survival rates, and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Health Network Cancer Institute - West Penn Hospital
Pittsburgh, Pennsylvania, 15224, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
SUNY Upstate Medical Center
Syracuse, New York, 13210, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.